Improved Anti-miRNA (AMOs) and Splice-Switching Oligonucleotides (SSOs), presented by Dr Mark Behlke, Chief Scientific Officer at Integrated DNA Technologies

GENE ASSOCIATION STUDIES OF SCHIZOPHRENIA & TARDIVE DYSKINESIA By Clement Zai A thesis submitted in conformity with the requirements For the degree of Doctor of Philosophy…

Muscle Diseases: The Muscular DystrophiesANRV295-PM02-04 ARI 13 December 2006 2:57 Muscle Diseases: The Muscular Dystrophies Elizabeth M. McNally and Peter Pytel Department

_© 2015. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2015) 8, 195-213 doi:10.1242/dmm.018424 195 ABSTRACT Duchenne muscular dystrophy

Molecular Characteristics of Duchenne Muscular Dystrophy in a Lebanese CohortVolume 12 • Issue 4 • 1000373J Mol Genet Med, an open access journal ISSN: 1747-0862

Viktor's Notes – Muscular DystrophiesDYSTROPHINOPATHIES – DUCHENNE, BECKER ......................................................................................

Muscular Dystrophy: A ReviewReview Article Muscular Dystrophy: A Review Naga Manjusha. Somavarapu*, Ramya krishna. Barma Department Of Pharmacology, Shri Vishnu College of

Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies Joe V. Chakkalakal,* Jennifer Thompson,* Robin J. Parks,†,‡ and

Microsoft Word - 03HB43-534 Matsuo.docTreatment of Duchenne Muscular Dystrophy with Oligo- nucleotides against an Exonic Splicing Enhancer Sequence Masafumi Matsuo, Mariko

Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophyOpen Access Publications et al. == on 08/06/2019 Downloadedfromhttps://journals.lww.com/md-journalbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3yRlXg5VZA8tbyynq2qmgvWB/ltZQBWO6vbh55IRMpQQTQPujiUoauw==on08/06/2019